anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To determine the views of health care professionals (HCPs) in South Western Sydney Local Health District (SWSLHD) about the effectiveness of implementation strategies used to increase routine height/length and weight screening, advice, and referral for children and adolescents. A secondary aim was to explore the prevalence of weight bias among HCPs.
METHODS: A questionnaire was sent to all HCPs who had undertaken online or face-to-face training between December 2018 and June 2020 in SWSLHD (n=840). The questionnaire collected data on their experience of routine height and weight screening and the effectiveness of strategies used in the implementation. It also included a weight bias assessment. Data were provided by the New South Wales (NSW) Ministry of Health on the performance of routine height/length and weight measures entered into the electronic medical records (eMR) in SWSLHD.
RESULTS: Of the 840 questionnaires sent, 87 were undeliverable; of the remaining 753, 285 were returned (38% response rate). More than half (53%, 151/285) of the participants were nurses. Most HCPs agreed that there was a need for routine screening and reported that education, training, and access to resources were the most helpful implementation strategies. Most HCPs were confident in performing routine screening but were less confident in raising the issue of weight with children and their families. Barriers to implementation were lack of time, equipment, appropriate clinical setting, and HCPs' perceptions and beliefs about obesity.
CONCLUSION: Routine screening is the first step in identifying children and adolescents at risk of overweight and obesity, but many HCP found it challenging to incorporate into daily practice. Multifaceted strategies are effective in increasing routine screening across diverse healthcare settings so that children and adolescents receive timely and appropriate intervention.
Epithelial-to-mesenchymal transition (EMT) is a complex cellular process that allows cells to change their phenotype from epithelial to mesenchymal-like. Type 3 EMT occurs during cancer progression. The aim of this study was to investigate the role of RNA-binding motif single-stranded interacting protein 3 (RBMS 3) in the process of EMT. To investigate the impact of RBMS 3 on EMT, we performed immunohistochemical (IHC) reactions on archived paraffin blocks of invasive ductal breast carcinoma (n = 449), allowing us to analyze the correlation in expression between RBMS 3 and common markers of EMT. The IHC results confirmed the association of RBMS 3 with EMT markers. Furthermore, we performed an in vitro study using cellular models of triple negative and HER-2-enriched breast cancer with the overexpression and silencing of RBMS 3. RT-qPCR and Western blot methods were used to detect changes at both the mRNA and protein levels. An invasion assay and confocal microscopy were used to study the migratory potential of cells depending on the RBMS 3 expression. The studies conducted suggest that RBMS 3 may potentially act as an EMT-promoting agent in the most aggressive subtype of breast cancer, triple negative breast cancer (TNBC), but as an EMT suppressor in the HER-2-enriched subtype. The results of this study indicate the complex role of RBMS 3 in regulating the EMT process and present it as a future potential target for personalized therapies and a diagnostic marker in breast cancer.
The invention discloses a Chinese herba preparation for treating a coronary heart disease. The Chinese herba preparation is prepared by the following traditional Chinese medicines in parts by weight: 20-150 parts of salvia miltiorrhiza, 20-100 parts of kudzuvine root, 10-100 parts of ligusticum wallichii, 1-50 parts of radix ophiopogonis, 1-50 parts of ginseng, 1-50 parts of pseudo-ginseng, 1-30 parts of hawthorn, 1-30 parts of trichosanthes kirilowii maxim, 1-30 parts of allium macrostemon and 1-30 parts of flowers carthami. The Chinese herba preparation is an oral preparation, a sub-lingual preparation and an injection preparation. The Chinese herba preparation is in such ways of tablets, capsules, granules, soft capsules, pills, syrups and injections. The salvia miltiorrhiza, the kudzuvine root, the ligusticum wallichii, the radix ophiopogonis, the ginseng, the pseudo-ginseng, the hawthorn, the trichosanthes kirilowii maxim, the allium macrostemon and the flowers carthami are mixed for use in the Chinese herba preparation, so as to obviously alleviate stenocardia and improve myocardial ischemia. The invention further provides a preparation method of the Chinese herba preparation for treating the coronary heart disease. The salvia miltiorrhiza, the kudzuvine root, the ligusticum wallichii, the radix ophiopogonis, the ginseng, the pseudo-ginseng, the hawthorn, the trichosanthes kirilowii maxim, the allium macrostemon and the flowers carthami are crushed proportionally, extracted with ethanol, purified by macroreticular resin, condensed and dried to obtain dried powder and an extract, and finally the preparation is obtained.
Gout is a common one of metabolic diseases in Taiwan. With the westernization of the national diet, cause Hyperuricemia and Gout gradually increased and getting younger and younger. Our invention use MSU to induce RAW 264.7 cell that xanthine oxidase has high active in cell. After RAW 264.7 cell treatment with miracle fruit water extract which xanthine oxidase active decrease along of concentration increases. When the concentration of 500 μ g/mL, xanthine oxidase active reply to control. And it effect better than Allopurinol (100 μ g/mL). Miracle fruit water extract has more effect when it together with vitamine C (100 μ g/mL). This is result confirm miracle fruit water extract can inhibit xanthine oxidase active, and then reduce uric acid in blood. Our invention also confirm it can scavenging reactive oxygen species. In summary, miracle fruit water extract not only inhibit xanthine oxidase active, but also scavenging reactive oxygen species. Miracle fruit is safety to eat and no side effect that can as patient's health food in diet.
Massage therapy for 10 minutes during quiet alert state following 9 AM feeding. Actigraph in place to measure sleep for 3 hours.
Participants in this group will be administered an oral, soft-gel, lookalike placebo. The participants will take the supplement themselves, orally, once per day, for 8 weeks.
Delefilcon A contact lenses worn first, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 14 days in a daily wear, daily disposable modality.
The control group followed the hospital's standard protocol. These do not include exercises or physiotherapy before 3 months after surgery.
First, patients with liver metastases from pancreatic cancer are given ablation of liver metastases, and conventional chemotherapy plus camrelizumab is performed 1 week after surgery. If patients have multiple metastases, ablation treatment needs to be performed in stages, each ablation After 1 week of treatment, sequential chemotherapy + camrelizumab were reinfused, and the efficacy was evaluated every 2 cycles until the disease progressed or the patient could not tolerate it.
Dentifrice with improved cleansing and polishing properties contains >=1 abrasive agent with a particle dia. of 1-15 mu, and a non-toxic Zn cpd. in an amt. of >=0.0065 wt. %. The abrasive agent is either (a) Ca pyrophosphate in an amt. of >=7.5 wt. % or (b) a hard abrasive agent selected from calcined Al2O3, Zr, silicate, crystalline SiO2, Ca silicate, KAlSi3O8 sand, SiC, pumice, ilmenite, CeO2, Fe2O3, ZrO2, SnO2 and topaz in an amt. to give the dentrifice a radioactively determined enamel abrasion (REA) value of >=400. When the abrasive is Ca pyrophosphate, the Zn cpd. is ZnO and is pre-mixed with the Ca pyrophosphate before incorporating into the dentifrice. When the abrasive is Zr silicate or crystalline SiO2, the Zn cpd. is ZnCl2 and/or ZnO. Incorporation of a Zn cpd. reduces the effect of the abrasive agent on the dental enamel without adversely affecting its effectiveness in removing resistant flecks and food residues from the tooth surface, so that a good polishing and cleansing effect is obtd. without the risk of damage to the enamel.
Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of three Phase III prototype tablets (Prototype 1, 2 or 3) in a crossover fashion.
A pre-screening consent will be obtained for NGS analysis on tumor tissue. Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the study, to have the possibility to follow the mutation using ctDNA. Main consent will be obtained after results of the NGS and before initiation of pembrolizumab. Computed Tomography (CT)-scan imaging will be done every 9 weeks as part of routine care practice. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks. Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 week. An additional measurement will be performed if treatment is stopped before the end of the study.

- Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes.
A reasonably stable water-in-oil skin moisturizer cream can be prepared from up to 90 or 95 parts by weight of an oil phase containing at least 5 weight percent cocoa butter and at least 5, preferably at least 10, parts by weight of water. Borax is preferably added to the water phase. The oil phase also contains 200-400 phr vegetable oil, based on the weight of cocoa butter. Mineral oil, a suitable ester wax, and, preferably, a suitable fatty acid ester emollient are also included in the oil phase. A fatty acid amine stearate helps to stabilize the skin cream. Despite the presence of both water and cocoa butter in the same composition, storage stability problems can be overcome, and the skin cream liquifies easily on the skin.
The invention provides a novel application of stilbeneglycoside to an antidepressant medicament. The stilbeneglycoside has low toxicity, and does not have the defects of calming, ataxia, induction of epilepsy and the like existing in the conventional antidepressant medicament. The stilbeneglycoside can be applied to preparation of a medicament for preventing and/or treating depression. The stilbeneglycoside can be added into a pharmaceutically-acceptable salt, ester or sugar for preparing a medicament for preventing or treating an antidepressant state. The stilbeneglycoside and the pharmaceutically-acceptable salt, ester or sugar thereof can be prepared into pharmaceutically-acceptable dosage forms such as tablets, capsules, oral liquids, injections and the like. The stilbeneglycoside has a wide application prospect on the aspects of health care and the like.
BACKGROUND: In-center hemodialysis (IHD) is the most common dialysis modality. Assisted peritoneal dialysis (assPD) is an option for frail and/or incapacitated patients. Both modalities can be used to alleviate uremic symptoms towards the end of life. There are few studies comparing these modalities. The primary aim is to compare hospital admissions between assPD and IHD. The secondary aim is to compare continuation of the dialysis modality and patient survival.
METHODS: Patients > 65 years, registered in the Swedish Renal Registry (SRR) and starting dialysis 2010-2017 were eligible for inclusion. Patients starting on assPD were matched with patients starting on IHD according to sex, Charlson Index, age and date for start of dialysis. Data were collected from SRR and other registries.
RESULTS: During the first year, patients on assPD and IHD had in median one (IQR 0-5.0; 0-4.0) hospitalization (p = 0.412). There was no significant difference after two years, in the annual number of days admitted to hospital, in hospitalizations with cardiovascular or infectious disease diagnoses or continuation of the dialysis modality, respectively. However, patients on assPD had a worse median survival (1.1 years IQR 0.6-2.1; IHD 3.1 years IQR 0.2-5.8; p < 0.001).
CONCLUSION: In this study patients starting assPD, often as a palliative treatment, showed no difference compared to IHD concerning the number of hospitalizations, number of days in hospital/year or continuation of the dialysis modality. Patients on assPD had a worse survival, which is likely due to residual confounding. Without that, patients on assPD would probably have lower number of hospitalizations. Despite limitations due to the retrospective observational design of the study, the results indicate that assPD is a feasible alternative to IHD when self-care dialysis is not possible and/or IHD too arduous.
NEW MATERIAL:The polypeptide of formula I. USE:Antiviral agent and carcinostatic agent. PREPARATION:For example, the plasmid of Escherichia coli MC1061/pGSII-102 (ATCC No.39668) is incised with a restriction enzyme. A synthetic promoter gene and the gene coding said polypeptide are cyclized with a DNA ligase using pBR327 as a vector to obtain plasmid pGSII-102. The plasmid is again incised with a restriction enzyme, and the oligonucleotide of formula II or formula III synthesized by the phosphoric acid triester process, etc. is integrated in the plasmid using T4DNA ligase. Escherichia coli MC1061 is transformed by the obtained plasmid pGI-201, and cultured in an agar medium to obtain the compound of formula I.
Sufentanil Citrate Injection, USP is a sterile, nonpyrogenic solution of sufentanil citrate in water for injection. Sufentanil Citrate is a potent opioid analgesic which is administered either epidurally or by intravenous injection.

Each mL contains sufentanil citrate equivalent to 50 mcg of sufentanil. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 4.2 (3.5 to 6.0).

The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended for use only as a single-use injection. When smaller doses are required, the unused portion should be discarded in an appropriate manner.

Sufentanil Citrate, USP, occurs as a white crystalline powder and is chemically designated as N-[-4-(methyoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide 2-hydroxy-1,2,3-propanetricarboxylate (1:1).

The molecular formula of sufentanil citrate is C22H30N2O2S∙C6H8O7 and the molecular weight is 578.69. Sufentanil Citrate has the following structural formula:
OBJECTIVES: To gain insight into the perceptions, and beliefs of patients with advanced cancer coping with chronic pain and to identify their attitudes and demands on pain management.
METHODS: From July to September 2022, 17 patients with advanced cancer living with chronic pain were recruited from a tertiary cancer hospital in Hunan Province, China. Qualitative and semi-structured interviews were conducted individually, with 30-45 minutes for each. The Colaizzi 7-step analysis method in phenomenological research was used for data analysis.
RESULTS: The experience of pain acceptance by advanced cancer patients with chronic pain was summarized into four themes: pain catastrophizing (unable to ignore the pain, try various methods to relieve the pain, exaggerating pain perception, and lack of knowledge about proper pain management), rumination (compulsive rumination and worrying rumination), avoidance coping (situational avoidance and repressive avoidance) and constructive action (setting clear value goal and taking reciprocal action).
CONCLUSION: Most patients with advanced cancer had low pain acceptance and negative attitudes. Feeling helpless in the face of pain and suffering alone were their norm. Long-term negative emotions could lead to gradual depression and loss of hope for treatment, resulting in pain catastrophizing and persistent rumination. Nevertheless, a few patients accepted pain with positive attitudes. Medical professionals should pay more attention to the psychological status of advanced cancer patients with chronic pain, and employ alternative therapies, for example, cognitive behavioral therapy. More efforts are needed to reduce patients' pain catastrophizing, and promote their pain acceptance by a better understanding of pain through health education.
A finger motion exercise assisting apparatus and related method receive input information from an external device. A prompter prompts a test subject with a prompt instruction to perform a finger motion exercise; and a finger motion catcher is used to catch finger motion data of the test subject. A finger motion analyzer includes an exercise item generator, a motion parameter calculator, and a finger function evaluator. On the basis of the input information, one or more exercise items are generated and an arranging order for the exercise items is determined. Each exercise item includes one or more prompt instructions. On the basis of the finger motion data, the motion parameter calculator calculates motion parameters characterizing a finger motion for each exercise item. Further, on the basis of the input information, the finger function evaluator compares the motion parameters with a motion parameter database, and outputs a comparison result.
PURPOSE: To objectively and quantitatively evaluate comfortableness by skin irritation brought by massaging by using smoothness, lightness of slip and warmness of a massaging material as indexes and to simply design a comfortable massaging material. CONSTITUTION: A massaging material is evaluated by using smoothness, lightness of slip and warmness of a massaging material as indexes. The smoothness is preferably shown by thickness of a massaging material felt in spreading on skin and, for example, can be obtained from a coefficient of friction of the massaging material and a variance value of a dynamic friction curve measured by a viscoelasticity measuring device. The lightness of slip is preferably shown by the degree of smallness of an integrated value of the sense of touch of massaging action and, for example, is obtained from an integrated value of the dynamic friction curve. The warmness is preferably shown by thermal conductivity.  To be concrete, for example, a massaging material containing a large amount of a liquid paraffin having a small integrated value of the dynamic friction curve, a low variance value and a low thermal conductivity has high evaluation when estimated by the evaluating method.
In the dose escalation portion, will enroll up to 42 subjects in six or more cohorts. The dose expansion portion will enroll up to 36 subjects. The actual number of subjects enrolled will depend on the safety data and additional evidence of antitumor activity but will not exceed an aggregate total of 85, including both the dose escalation and expansion phases.
BACKGROUND: Coronavirus disease 2019 (COVID-19) has affected individuals worldwide, and patients with cancer are particularly vulnerable to COVID-19-related severe illness, respiratory failure, and mortality. The relationship between COVID-19 and cancer remains a critical concern, and a comprehensive investigation of the factors affecting survival among patients with cancer who develop COVID-19-related respiratory failure is warranted. We aim to compare the characteristics and outcomes of COVID-19-related acute respiratory failure in patients with and without underlying cancer, while analyzing factors affecting in-hospital survival among cancer patients.
METHODS: We conducted a retrospective observational study at Taipei Veterans General Hospital in Taiwan from May to September 2022, a period during which the omicron variant of the severe acute respiratory syndrome coronavirus 2 was circulating. Eligible patients had COVID-19 and acute respiratory failure. Clinical data, demographic information, disease severity markers, treatment details, and outcomes were collected and analyzed.
RESULTS: Of the 215 enrolled critically ill patients with COVID-19, 65 had cancer. The patients with cancer were younger and had lower absolute lymphocyte counts, higher ferritin and lactate dehydrogenase (LDH) concentrations, and increased vasopressor use compared with those without cancer. The patients with cancer also received more COVID-19 specific treatments but had higher in-hospital mortality rate (61.5% vs 36%, P = 0.002) and longer viral shedding (13 vs 10 days, P = 0.007) than those without cancer did. Smoking [odds ratio (OR): 5.804, 95% confidence interval (CI): 1.847-39.746], elevated LDH (OR: 1.004, 95% CI: 1.001-1.012), vasopressor use (OR: 5.437, 95% CI: 1.202-24.593), and new renal replacement therapy (OR: 3.523, 95% CI: 1.203-61.108) were independent predictors of in-hospital mortality among patients with cancer and respiratory failure.
CONCLUSION: Critically ill patients with cancer experiencing COVID-19-related acute respiratory failure present unique clinical features and worse clinical outcomes compared with those without cancer. Smoking, elevated LDH, vasopressor use, and new renal replacement therapy were risk factors for in-hospital mortality in these patients.
OBJECTIVES: The Health Self-Care Neglect (HSCN) scale is a measure of self-care neglect developed for use in informal caregivers, where self-care is defined as behaviors undertaken to maintain health. There was no formal psychometric analysis of the scale, so we tested a 9-item, dichotomous-response version of the HSCN scale in a sample of 250 informal caregivers of adults with chronic heart failure.
METHODS: As the indicators of self-care neglect were considered formative (influencing the latent variable directly) rather than reflective (influenced by the latent variable), we used a procedure for the specification of formative measurement models. First, maximally correlated composites of indicators were identified for the latent variable, and optimal scoring weights were developed. Then, the reflective factor was tested with confirmatory factor analysis, and longitudinal invariance of the factorial structure was tested by introducing model constraints. Reliability was assessed with composite reliability model-based estimates. Concurrent validity was assessed by correlating the HSCN scale total score with the maintenance scale score of the Self-Care Inventory.
RESULTS: Strict invariance, the highest level possible, was achieved. Reliability was 0.81 at baseline. Concurrent validity was demonstrated ( r = -0.475, P < .0001).
CONCLUSION: The results of this analysis indicate that the HSCN scale is reliable, stable, and valid as a measure of health self-care neglect when tested in a sample of caregivers. The HSCN scale measures the successful performance of self-care, whereas existing measures of self-care reflect intention. Understanding both intention and behavior is useful, so we recommend using the HSCN scale in addition to existing measures of self-care.
NEW MATERIAL:A monoclonal antibody NE-25, capable of carrying out antigen- antibody reaction with a protein antigen, present in human pulmonary parvicellular cancer and having 25X10<3> daltons molecular weight, having the following properties and belonging to IgG1 isotype. Reactive with human pulmonary parvicellular cancer, neuroglioma and neuroblastoma as well as normal cells of human nerve, thyroid gland and adrenal gland. Unreactive with normal tissues of human lungs, stomack, small intestines, colon and kidney. USE:A diagnostic agent for human pulmonary cancer. PREPARATION:For example, a cultivated strain of a pulmonary parvicellular cancer is administered to immunize a BALB/C mouse and splenic cells are collected and subjected to cell fusion with myelomatous cells to give a hybridoma, which is then cloned by a limiting dilution method, etc., and monocloned. The resultant hybridoma is further administered to a mouse abdominal cavity, etc., and multiplied to afford the aimed monoclonal antibody from the ascites.